Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Genentech

< Previous 1 2 3 4 Next >
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
From Genentech
Via Business Wire
Tickers RHHBY
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
From Genentech
Via Business Wire
Tickers RHHBY
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
From Genentech
Via Business Wire
Tickers RHHBY
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
Tickers RHHBY
Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
From Genentech
Via Business Wire
Tickers RHHBY
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
From Genentech
Via Business Wire
Tickers RHHBY
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
Tickers RHHBY
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS